Foghorn Therapeutics Earnings Estimate

By analyzing Foghorn Therapeutics' earnings estimates, investors can diagnose different trends across Foghorn Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Foghorn Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options. Foghorn Therapeutics is projected to generate -0.420825 in earnings per share on the 31st of December 2024. Foghorn Therapeutics earnings estimates module stress-tests analyst consensus about projected Foghorn Therapeutics EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as Foghorn Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Foghorn Therapeutics' earnings estimates, investors can diagnose different trends across Foghorn Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. Gross Profit is likely to rise to about (71.8 M) in 2024. Pretax Profit Margin is likely to drop to -2.9 in 2024Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Foghorn Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.